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The Breast Cancer Stem Cell Potency of Copper(II) Complexes 
Bearing Nonsteroidal Anti-Inflammatory Drugs and Their 
Encapsulation Using Polymeric Nanoparticles 
Arvin Eskandari,a Janine N. Boodram,a Paul B. Cressey,a Chunxin Lu,a Peter M. Bruno,b Michael T. 
Hemann,b and Kogularamanan Suntharalingama* 
We report the cancer stem cell (CSC) potency of a novel series of copper(II)-phenanthroline complexes bearing  
nonsteriodial anti-inflammotory drugs; naproxen, tolfenamic acid, and indomethacin (2a-3c). Two of the complexes, 2a 
and 3c, kill breast CSC-enriched HMLER-shEcad cells (grown in both monolayer and three-dimensional cell cultures) to a 
significantly better extent than salinomycin, a well-established CSC toxin. The most potent complex in the series, 3c 
induces its cytotoxic effect by generating intracellular reactive oxygen species (ROS) and inhibiting cyclooxgenase-2 (COX-
2) activity. Encapsulation of 3c using biodegradable methoxy poly(ethylene glycol)-b-poly(D,L-lactic-co-glycolic) acid (PEG-
PLGA) copolymers at the appropriate feed (5%, 3c NP5) enhances breast CSC uptake and reduces overall toxicity. The 
nanoparticle formulation, 3c NP5 selectively kills breast CSCs over bulk breast cancer cells, and evokes a similar cellular 
response to the payload, 3c. To the best of our knowledge, this is the first study to demonstrate that polymeric 
nanoparticles can be used to effectively deliver CSC-potent metal complexes into CSCs.   
Introduction 
Cancer stem cells (CSCs) are a distinct population of tumour 
cells that have the ability to self-renew, differentiate, and form 
metastatic tumours.1 CSCs effectively evade conventional 
chemotherapy and radiotherapy as these treatments 
specifically target fast growing cancer cells, and CSCs, due to 
their stem cell-like properties, divide more slowly.2 After 
surviving treatment, CSCs are able to regenerate the original 
tumour and/or produce invasive cancer cells that are able to 
colonise distant organs.3  For these reasons, CSCs are widely 
thought to be responsible for cancer relapse.4 Therefore, to 
provide a durable response and prevent tumour recurrence, 
chemotherapeutics must have the ability to remove the entire 
population of cancer cells, including CSCs. Therapeutic 
strategies capable of selectively killing CSCs and disrupting the 
microenvironments (niches) supporting these cells are the 
focus of several research programmes.5,6 Potential CSC 
therapeutic targets such as cell surface markers7-11 and various 
deregulated signalling pathways12-14 have been identified, but 
there is still no clinically approved drug that specifically kills 
CSCs. Most of the compounds undergoing pre-clinical or 
clinical investigation as CSC-specific agents are completely 
organic in nature.2 The anti-CSC properties of metal-containing 
compounds are largely unexplored.15-17 
We recently reported a series of copper(II)-phenanthroline 
complexes containing the nonsteroidal anti-inflammatory drug 
(NSAID), indomethacin, capable of selectivity killing breast 
CSCs over bulk breast cancer cells.18 The most effective 
compound in this series, 1 (see Fig. 1) induced breast CSC 
toxicity by generating intracellular reactive oxygen species 
(ROS) and inhibiting cyclooxygenase-2 (COX-2), an enzyme that 
catalyses prostaglandins (PG) formation and involved in 
inflammatory response. The breast CSC selectivity of 1 is 
thought to arise from its ability to exploit the vulnerability of 
breast CSCs to changes in their intracellular redox state,19,20 
and the differential expression of COX-2 in breast CSCs and 
bulk breast cancer cells.18,21,22 Here, we have sought to 
increase the CSC potency of the copper(II)-phenanthroline 
series by, (i) increasing their inherent lipophilicity (to improve 
 
Fig. 1 Chemical structure of a copper(II)-phenanthroline complex 
bearing two indomethacin molecules, which was previously reported to 
selectively kill breast CSCs over bulk breast cancer cells.  
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cell uptake and nanoparticle encapsulation, vide infra), and (ii) 
varying the NSAID component. Specifically, 3,4,7,8-
tetramethyl-1,10-phenanthroline and 4,7-diphenyl-1,10-
phenanthroline were used to increase hydrophobicity, while 
naproxen, tolfenamic acid, and indomethacin were used to 
modulate COX-2 activity.  
 Nanoparticles offer a method to unambiguously deliver 
chemotherapeutics to tumours (including CSCs).23 Further, 
nanosystems increase drug solubility, bioavailability, drug half-
life, and reduce off-target toxicity.24,25 Spherical nanoparticles 
with diameters ranging from 100-200 nm can passively target 
cancer cells by taking advantage of the enhanced permeability 
and retention (EPR) effect in tumour tissues.26,27 Several 
spherical nanoparticle formulations exist, including those 
based on iron-oxide, gold, liposomes, and polymers.28 A 
number of these formulations are currently used in the clinic 
to deliver chemotherapies to tumours.29 Nanoparticles 
comprising of polymers are of particular interest due to their 
synthetic versatility and tuneable properties.30 Polymeric 
nanoparticles have been widely used to deliver metallodrugs 
to cancer cells in vitro and in vivo,31-34 however, their ability to 
transport CSC-potent metal complexes into CSCs has not been 
investigated. It should be noted that nanoparticle platforms 
for CSC-targeted drug delivery of non-metal based 
therapeutics have been reported.35-38 In the present, proof-of-
concept study, we use the biodegradable, amphiphilic 
copolymer, methoxy poly(ethylene glycol)-b-poly(D,L-lactic-co-
glycolic) acid (PEG-PLGA), to encapsulate and deliver the most 
CSC-potent and -selective copper(II) complex in the reported 
series, 3c, into breast CSCs.   
 
Results and discussion 
Synthesis and characterisation 
The copper(II) complexes investigated in this study are 
depicted in Fig. 2. The copper(II)-NSAID complexes, 2a-3c were 
prepared by reacting CuCl2•2H2O with 3,4,7,8-tetramethyl-
1,10-phenanthroline or 4,7-diphenyl-1,10-phenanthroline and 
two equivalents of the appropriate NSAID ligand (naproxen, 
tolfenamic acid, or indomethacin) in methanol, under basic 
conditions. The copper(II) complexes were isolated as green or 
blue solids and were fully characterised by mass spectrometry, 
infra-red spectroscopy, and elemental analyses (full details 
reported in the Supporting Information). 
The lipophilicity of the copper(II)-NSAID complexes, 2a-3c 
was determined by measuring the extent to which they 
partitioned between octanol and water, P. The experimentally 
determined Log P values for 2a-3c varied between 0.89 and 
1.01 (Table S1). The hydrophobic nature of the complexes 
suggests that 2a-3c will be readily absorbed by cells. UV-Vis 
spectroscopy studies were performed to evaluate the stability 
of 3c, taken as a representative member of the copper(II)-
NSAID series, in biologically relevant solutions. In PBS 
containing whole cell lysate (5 x 103 HMLER-Ecad cells), 3c (50 
µM) is reasonably stable over a period of 24 h at 37 oC (Fig. 
S1). In the presence of ascorbic acid (500 µM in PBS, 10 
equivalence), a cellular reductant, the absorption of 3c 
markedly decreased over 24 h (Fig. S2). The lower stability of 
3c in the presence of ascorbic acid is most likely a result of 
reduction of the metal centre from copper(II) to copper(I). 
Before carrying out cellular studies, the stability of 3c in 
mammary epithelial cell growth medium (MEGM) was 
investigated at 37 oC (Fig. S3). Under these conditions, 3c is 
adequately stable over the course of 24 h.  
 
 Potency towards breast CSC-enriched and CSC-depleted cells 
 In order to determine the breast CSC potency and 
selectivity (over bulk breast cancer cells) of 2a-3c, two human 
mammary epithelial cell lines were used; HMLER and HMLER-
shEcad cells. HMLER cells express a stable CSC-like population 
of 5−8%, whereas HMLER-shEcad cells exhibit a 90% CSC-like 
population.39 The cytotoxicity of 2a-3c towards HMLER and 
HMLER-shEcad cells was measured using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. 
IC50 values (concentrations required to induce 50% viability) 
were determined from dose-response curves (Fig. S4-5) and 
are summarised in Table 1 and S2. Salinomycin, a natural 
Table 1. IC50 values of the copper(II) - nonsteroidal anti-Inflammatory drug 
complexes, 1-3c, cisplatin, dichloro(1,10-phenanthroline)copper(II), and  
salinomycin against HMLER and HMLER-shEcad cells. 
Compound HMLER 
IC50 [μM] a 
HMLER-shEcad 
IC50 [μM] a 
1 b 7.38 ± 0.30 2.21 ± 0.46 
2a 0.54 ± 0.27 0.28 ± 0.03  
2b 4.71 ± 1.08 2.42 ± 0.12 
2c 0.59 ± 0.25 0.79 ± 0.06 
3a 0.27 ± 0.09 0.25 ± 0.04 
3b 0.88 ± 0.30 2.65 ± 0.04 
3c 0.46 ± 0.16 0.23 ± 0.04 
cisplatin 3.44 ± 0.47 4.85 ± 0.36 
dichloro(1,10-
phenanthroline)copper(II) b 
4.90 ± 0.17 7.86 ± 0.26 
salinomycin  16.43 ± 2.09 5.63 ± 0.11 
aDetermined after 72 h incubation (mean of three independent 
experiments ± SD). b Reported in reference 18. 
Fig. 2 Structures of the copper(II)-phenanthroline complexes bearing 
NSAIDs (naproxen, tolfenamic acid, or indomethacin) that are under 
investigation.  
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product that was previously shown to specifically inhibit breast 
CSC proliferation, was used as a positive control (Fig. S6).39 
Cisplatin and dichloro(1,10-phenanthroline)copper(II) (chosen 
as a representative copper(II) complex without a NSAID 
moiety) were included as additional controls (Fig. S7). The 
copper(II)-NSAID complexes, 2a-3c displayed micromolar or 
sub-micromolar potency towards both cell lines. Two of the 
complexes, 2b and 3c displayed significantly greater potency (p 
< 0.05) for CSC-enriched HMLER-shEcad cells than CSC-
deficient HMLER cells. The naproxen and indomethacin 
bearing complexes, 2a and 3c exhibited greater potency 
toward HMLER-shEcad cells than salinomycin (up to 24-fold), 
cisplatin (up to 21-fold), and dichloro(1,10-
phenanthroline)copper(II) (up to 34-fold). However it should 
be noted that salinomycin is 3-fold more cytotoxic towards 
HMLER-shEcad cells than HMLER cells, whereas the copper(II) 
complexes are, at most, only 2-fold more selective. Notably, 
the copper(II) complexes, 2a and 3c exhibited 10-fold higher 
potency for HMLER-shEcad cells than 1 (IC50 = 2.2 μM), the 
lead compound from our previous study.18 Naproxen was non-
toxic towards both cell lines (> 100 μM) whereas tolfenamic 
acid displayed moderate activity (Fig. S8-9). This is consistent 
with the low cytotoxicity previously observed for 
indomethacin.18  
 
Cellular uptake by breast CSC-enriched HMLER-shEcad cells 
 Cellular uptake studies were conducted to determine the 
CSC permeability of the copper(II) complexes, 2a-3c. HMLER-
shEcad cells were incubated with 2a-3c (at their respective IC50 
values for 12 h) and the intracellular copper concentration was 
determined by inductively coupled plasma mass spectrometry 
(ICP-MS). The copper(II) complexes, 2a-3c were readily taken 
up by HMLER-shEcad cells, with whole cell uptake ranging 
from 56.0 ± 0.5 ppb of Cu/ million cells for 2a to 120.9 ± 1.0 
ppb of Cu/ million cells for 2c (Fig. 3). A modest correlation 
between cell uptake and the NSAID or phenanthroline 
component was observed. Complexes containing 
indomethacin (2c and 3c) were internalised better than those 
bearing tolfenamic acid (2b and 3b) or naproxen (2a and 3a). 
Complexes possessing 4,7-diphenyl-1,10-phenanthroline (3b 
and 3c) were taken up marginally better than those containing  
3,4,7,8-tetramethyl-1,10-phenanthroline (2b and 2c).  The 
relatively small variation in cell uptake across the copper(II) 
complexes (64.9 ppb of Cu/ million cells) is consistent with 
their similar lipophilicities (Log P values, Table S1). The 
indomethacin-appended complexes, 2c and 3c exhibited 
greater cell penetration (up to 2.2-fold) than 1 (which also 
contains indomethacin) under identical conditions. This was 
expected as the 3,4,7,8-tetramethyl-1,10-phenanthroline and 
4,7-diphenyl-1,10-phenanthroline ligands present in 2c and 3c 
are more hydrophobic, and thus more susceptible to passive 
uptake, than the amine substituted phenanthroline ligand 
found in 1. A direct correlation between cellular uptake and 
cytotoxicity was not observed for 2a-3c. 
 
Mammosphere potency 
Breast CSCs when grown in serum-free media, under low-
attachment conditions are capable of forming three-
dimensional, tumour-like structures called mammospheres.40 
The ability of a given compound to inhibit mammosphere 
formation from single cell suspensions (with respect to 
number and size) is often used as a marker for CSC potency. 
The ability of 2a, 2b, and 3c to inhibit HMLER-shEcad 
mammosphere formation (at their respective IC20 values after 
5 days incubation) was assessed using an inverted microscope. 
Incubation with 2a, 2b, and 3c markedly reduced the number 
and size of mammospheres formed (Fig. 4 and S10). Incubation 
with cisplatin (at the IC20 value after 5 days incubation) also 
reduced the size of mammospheres formed but to a lesser 
extent than 2a, 2b, and 3 (Fig. 4). Treatment with free NSAIDs; 
naproxen, tolfenamic acid, or indomethacin did not 
significantly affect the number of mammospheres formed (Fig. 
S10). In order to determine the ability of 2a, 2b, and 3c to 
reduce mammosphere viability, TOX8, a resazurin-based 
reagent, was used. The IC50 values (concentration required to 
reduce mammosphere viability by 50%) were extrapolated 
from dose-response curves (Fig. S11) and are summarised in 
Table S3. The IC50 values for 2a, 2b, and 3c were in the sub-
micromolar range, and significantly lower (up to 25-fold) than 
that reported for salinomycin under the same conditions.41 
The mammosphere potencies of 2a, 2b, and 3c were also 
better than 1 (up to 6-fold, Fig. S12), cisplatin (up to 12-fold), 
and dichloro(1,10-phenanthroline)copper(II) (up to 14-fold, 
Fig. S13). The anti-mammosphere properties observed for 2a, 
2b, and 3c are highly desirable in terms of selecting CSC drug 
candidates for preclinical studies. 
 
Insight into the cytotoxic mechanism of action of 3c 
To elucidate the possible mechanism of action of the most 
potent copper(II) complex, 3c we utilised a mechanism of action 
predictive functional genetic assay based on RNAi.42,43  This 
methodology has been previously applied to shed light on the 
 
Fig. 3 Copper content in HMLER-shEcad cells untreated and treated with 
2a-3c and 1 (at their respective IC50 values for 12 h). 
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Fig. 4 Representative bright-field images (× 10) of HMLER-shEcad 
mammospheres in the absence and presence of 2a, 2b, 3c, and cisplatin 
after 5 days incubation. 
control 2a 2b 3c cisplatin
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mechanism of action of combinations of chemotherapeutics as well 
as metal-based anticancer agents.17,44-46 The approach relies on 
murine cancer cells that are infected with eight green fluorescent 
protein (GFP)-tagged shRNAs.  Each shRNAs confers resistance or 
sensitivity to a given compound according to its mechanism of 
action.  Thus, the pattern of resistance and sensitivity of the eight 
shRNAs to a compound of interest can be compared to a reference 
set of compounds of known mechanism of action.  Using this 
method, we found that the pattern of resistance and sensitivity for 
3c did not relate to any of the compounds in the reference set, 
which includes all classes of clinical used cytotoxic agents and some 
recently developed targeted inhibitors.  However, when comparing 
3c to cytotoxic agents that are not part of the reference set, the 
two most similar compounds were dichloro(1,10-
phenanthroline)copper(II) and a rhenium(V)-oxo complex 
previously characterized as a ROS-producing, necroptotosis-
inducing agent (Fig. 5).18,45  By comparing the relative Euclidian 
distances between 3c, its closest compounds, and the relationship 
between and within categories of the reference set, the likelihood 
that 3c is related to compounds with unknown mechanisms (within 
our database) can be determined. The average of the absolute sum 
of the Euclidian distances from 3c to dichloro(1,10-
phenanthroline)copper(II) and the rhenium(V)-oxo complex are 
1.62 and 2.06, respectively.  However, the intra-category and inter-
category distances of the reference set are 0.99 ± 0.38 and 2.69 ± 
0.44, respectively.  Thus, the intermediate degree of these 
similarities is suggestive of related, yet distinct, mechanisms of 
action (Table S4-5). Interestingly, the Euclidian distance of 3c from 1 
was 2.94 (Table S6), suggesting that 3c and 1 exhibit similar but 
distinct mechanisms of action (Fig. S14). 
 
Intracellular reactive oxygen species (ROS) production by 3c 
Given the related mechanism of cytotoxicity of 3c and known 
ROS-inducing metal complexes (according to the RNAi assay 
prediction), we investigated the ability of 3c to generate ROS in 
CSC-enriched HMLER-shEcad cells using 6-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA), a fluorescence-
based ROS indicator. HMLER-shEcad cells incubated with 3c (0.5 μM 
for 6, 12, and 48 h) displayed significantly higher levels of ROS (p < 
0.05) compared to untreated cells (Fig. S15-17). A similar 
enhancement in ROS levels was observed for H2O2-treatment (6 μM 
for 6, 12, and 48 h) (Fig. S15-17). Co-incubation with N-
acetylcysteine (1.5 mM for 6, 12, and 48 h, a ROS scavenger) 
reduced 3c- and H2O2-mediated ROS generation (Fig. S15-17). 
Intracellular generation of ROS can activate stress-activated protein 
kinase (SAPK)/Jun amino-terminal kinase (JNK) and p38 MAP kinase 
(MAPK) pathways.47 Immunoblotting studies showed that HMLER-
shEcad cells treated with 3c (0.25-0.5 μM for 72 h) displayed 
increased expression of phosphorylated p38 MAPK and SAPK/JNK, 
and their downstream targets, phosphorylated MAP kinase-
activated protein kinase 2 (MAPKAPK-2) and c-Jun (Fig. S18). The 
activation of SAPK/JNK and p38/MAPK pathways can trigger 
apoptosis.48  HMLER-shEcad cells dosed with 3c (0.25-0.5 μM for 72 
h) expressed noticeably higher levels of cleaved caspase-3 and -7 
compared to untreated cells, indicative caspase-dependent 
apoptosis (Fig. S18). Taken together, the data shows that 3c is able 
to enhance intracellular ROS levels, activate SAPK/JNK and 
p38/MAPK pathways, and induce apoptotic cell death. The potency 
of 3c towards HMLER-shEcad mammospheres grown in the 
presence of N-acetylcysteine (1.5 mM) decreased significantly (p < 
0.05) (Fig. S19 and Table S7). Under these conditions, the ability of 
3c (at the IC20 value after 5 days incubation) to reduce the number 
and size of mammospheres formed was also markedly attenuated 
(Fig. S20-21). This indicates that the CSC targeting potential of 3c is, 
in part, related to its ability to induce ROS.  
 
COX-2 inhibition contributes to 3c-mediated CSC death  
COX-2 modulates cell proliferation and apoptosis in solid tumours 
including breast cancers.49 COX-2 is also implicated in CSC 
proliferation and dissemination.21,50 The COX-2 inhibitory properties 
of 3c and indomethacin (positive control) were investigated using 
an enzyme immunoassay (EIA). COX-2 dosed with 3c (0.05-50 µM, 
37 oC) displayed a marked decrease in activity (conversion of 
arachidonic acid to PG) compared to untreated control samples 
with 100% COX-2 activity (Fig. S22). Indomethacin (0.05-50 µM, 37 
oC) inhibited COX-2 activity to a similar extent to 3c (the fact that 3c 
contains two indomethacin groups per compound was taken into 
account in). Collectively the results show that despite the 
attachment of indomethacin to copper in 3c, its COX-2 inhibitory 
effect is retained. Notably, the COX-2 inhibitory effect of 3c was 
markedly better than that previously observed for 1.18 In order to 
determine if the cellular mechanism of action of 3c involves COX-2 
downregulation, immunoblotting (Fig. S23) and flow cytometric 
(Fig. S24A) studies were performed. HMLER-shEcad cells pre-
treated with lipopolysaccharide (LPS) (2.5 µM for 24 h), to increase 
basal COX-2 levels, and treated with 3c (0.25-0.5 μM for 48 h) or 
indomethacin (20 μM for 48 h) exhibited a marked decrease in COX-
2 expression suggesting that the cytotoxic effect of 3c may involve 
COX-2 downregulation. Cisplatin (5 μM) and dichloro(1,10-
phenanthroline)copper(II) (8 μM)  did noticeably alter COX-2 
expression (Fig. S24B). To determine if 3c evokes COX-2-dependent 
CSC death, cytotoxicity studies were performed with HMLER-shEcad 
cells in the presence and absence of prostaglandin E2 (PGE2) (20 
μM, 72 h), the product of COX-2-mediated arachidonic acid 
metabolism. The potency of 3c towards HMLER-shEcad cells 
decreased in the presence of PGE2 (2-fold, p < 0.05) (Fig. S25), 
suggesting that 3c induces COX-2-dependent CSC death. Additional 
studies showed that the potency of 3c towards HMLER-shEcad 
 
Fig. 5 RNAi signatures derived from the treatment of Eμ-Mycp19arf−/− 
lymphoma cells with a) 3c, b) dichloro(1,10-phenanthroline)copper(II), 
and c) the necroptosis-inducing rhenium(V)-oxo complex at the LD80−90 
concentration for each compound. 
a)
b)
c)
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mammospheres grown in the presence of LPS (2.5 µM), and PGE2 
(20 μM) decreased significantly (p < 0.05) (Fig. S19 and Table S7). 
Under these conditions, the ability of 3c (at the IC20 value after 5 
days incubation) to inhibit mammospheres formation was also 
markedly attenuated (Fig. S20-21). Therefore the ability of 3c to 
inhibit COX-2 contributes to its CSC targeting potential. 
 
PEG-PLGA nanoparticle encapsulation of 3c  
Biodegradable PEG-PLGA copolymers are amphiphilic, and thus 
self-assemble in aqueous conditions to form spherical nanoparticles 
with a hydrophilic PEG outer shell and a hydrophobic PLGA core.51 
The lipophilic copper complex, 3c (Log P = 1.01) was encapsulated 
into the hydrophobic core of PEG-PLGA (5000:30000 Da, 1:1 LA:GA) 
nanoparticles using the nanoprecipitation method (Fig. 6A). 
Nanoparticles (3c NP2.5-50) were prepared using a range of feeds 
(2.5-50%), where feed refers to the percentage (w/w) of 3c to 
polymer. The loading and encapsulation efficiency of 3c was 
determined for each formulation by measuring the copper content 
of the nanoparticles using ICP-MS (after degradation with nitric 
acid). The change in loading and encapsulation efficiency as 
function of feed is depicted in Fig. 6B. Maximum encapsulation 
(where encapsulation efficiency = 1.4% and loading efficiency = 
0.07%) was achieved at 5% feed (3c NP5). Characterisation of 3c NP5 
by dynamic light scattering (DLS) showed that the nanoparticle 
diameter was 145 ± 10 nm, and the polydispersity was 0.218 ± 
0.041 (Fig. S26). The nanoparticle size is consistent with previously 
reported metal complex-polymer formulations.24,31,52 Due to the 
PEG outer shell, 3c NP5 is negatively charged (zeta-potential = 
−17.5 mV, Fig. S27). The nanoparticle formulation, 3c NP5 is stable 
under physiologically relevant conditions (PBS, pH 7.4 with 10% FBS, 
at 37 oC) over the course of 72 h (Fig. S28), and is able to release an 
appreciable amount of the payload (3c) under similar conditions 
(PBS, pH 7.4 at 37 oC over 72 h) (Fig. 6C).  
 
Breast CSC uptake, potency, and mechanism of action of the 
nanoparticle formulation, 3c NP5 
To determine if the nanoparticle construct, 3c NP5 can enter 
CSCs, cellular uptake studies were performed. HMLER-shEcad cells 
were incubated with 3c NP5 (0.5 µM for 4 h) at 37 oC, and the 
intracellular copper content was measured by ICP-MS. The 
nanoparticle formulation, 3c NP5 was readily taken up by cells 
under these conditions (174.3 ± 1.3 ppb of Cu/ million cells). The 
intracellular copper concentration was in fact 10-fold higher than 
that of the free compound, 3c under the same conditions (Fig. S29). 
To determine if uptake was temperature dependent (and thereby 
active or passive), a similar experiment was conducted at 4 oC (Fig. 
S29). HMLER-shEcad cells incubated with 3c NP5 (0.5 µM for 4 h) at 
4 oC, displayed a 71% decrease in copper uptake, indicative of 
active uptake. Polymeric nanoparticles, such as PEG-PLGA are 
prone to undergo energy- and temperature-dependent 
endocytosis.53 To discern if 3c NP5 undergoes endocytosis, HMLER-
shEcad cells were incubated (for 12 h) with endocytosis inhibitors, 
namely ammonium chloride (50 mM for 2 h) and chloroquine (100 
μM for 2 h) prior to treatment with 3c NP5 (0.5 µM for 12 h) and 
determination of the intracellular copper levels. Under these 
conditions, a statistically significant (p < 0.01) decrease in uptake 
was observed (Fig. S30), suggesting that 3c NP5 enters CSCs via an 
endocytic pathway. Entities taken up by endocytosis are 
internalised into endosomes which are acidic. Therefore we 
investigated the ability of 3c NP5 to release its payload, 3c, under 
acidic conditions (sodium acetate buffer, pH 5.2 at 37 oC over 72 h). 
The nanoparticle formulation, 3c NP5 readily releases its payload 
under these conditions (Fig. 6C), implying that it is capable of 
releasing 3c in cells, upon endocytic uptake. 
To determine if 3c NP5 can recapitulate the breast CSC potency 
and selectivity of the payload, 3c, cytotoxicity studies were 
conducted with HMLER and HMLER-shEcad cells. The nanoparticle 
formulation, 3c NP5 exhibited sub-micromolar IC50 values towards 
both cell lines (IC50 = 0.91 ± 0.02 µM for HMLER cells and IC50 = 0.22 
± 0.03 µM for HMLER-shEcad cells, Fig. 6D). Notably, 3c NP5 was 
less toxic towards HMLER cells than free 3c (p < 0.05, 2-fold). This is 
expected, as polymeric nanoparticles are well known to reduce the 
toxicities of incorporated compounds.54 Similarly to the payload, 3c 
NP5 displayed CSC-selective potency (IC50 value for HMLER cells was 
4-fold higher than that for HMLER-shEcad cells), which suggests that 
the mechanism of cytotoxicity of 3c NP5 and 3c may be related. The 
payload, 3c was found to induce its cytotoxic effect by generating 
intracellular ROS and inhibiting COX-2 activity (supra vide). To 
decipher if the nanoparticle formulation, 3c NP5 is able to retain the 
mechanism action of the payload, further studies were performed. 
HMLER-shEcad cells incubated with 3c NP5 (0.5 μM for 48 h) 
displayed significantly higher levels of ROS (p < 0.05) compared to 
untreated cells (Fig. S31). This shows that 3c NP5 is able to generate 
intracellular ROS, like the payload (free 3c), albeit to a lesser extent. 
HMLER-shEcad cells pre-treated with LPS (2.5 µM for 24 h) and 
dosed with 3c NP5 (0.5-1 μM for 72 h) displayed a drastic decrease 
in COX-2 levels as evidenced by immunoblotting (Fig. S23) and flow 
 
Fig. 6 A) Schematic representation of the preparation of 3c NP5 using the 
nanoprecipitation method. B) The effect of feed variation on loading and 
encapsulation efficiency of 3c incorporated into PEG-PLGA nanoparticles. 
C) The amount of copper released from 3c NP5 upon incubation in PBS (pH 
7.4) or sodium acetate buffer (pH 5.2) over the course of 72 h at 37 oC. D) 
Representative dose-response curves for the treatment of HMLER-shEcad 
and HMLER cells with 3c NP5 after 72 h incubation. 
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cytometric studies (Fig. S24A). This is comparable to the COX-2 
downregulation induced by the payload. Collectively, this shows 
that encapsulation of 3c by PEG-PLGA copolymers does not alter its 
cellular properties, which augers well for future in vivo 
development.  
Conclusions 
In summary we report the synthesis and characterisation of six 
novel copper(II)-phenanthroline complexes bearing NSAIDs 
(naproxen, tolfenamic acid, and indomethacin) and their anti-
CSC properties in vitro. The copper(II) complexes displayed 
micromolar or sub-micromolar potency towards breast CSC-
enriched HMLER-shEcad cells grown in mono- and three-
dimensional cell cultures. The CSC potency of two of the 
complexes, 2a and 3c were significantly higher than that of 
salinomycin, a breast CSC-specific natural product identified in 
a 16,000 compound screen,39 and 1, a related copper(II)-
phenanthroline complex recently reported by our group.18 The 
same complexes also displayed greater mammosphere-
potency than that reported for clinically used drugs; cisplatin, 
paclitaxel, and vinorelbine.41 Further, 2b and 3c displayed 
selective potency for CSCs over bulk cancer cells (2-fold), albeit 
this is lower than that exhibited by salinomycin (3-fold). 
Detailed mechanistic studies suggest that the cytotoxic 
mechanism of action of the most effective complex, 3c 
involves intracellular ROS generation and COX-2 inhibition. 
Given our results, it is evident that by combining ROS-
generating copper(II)-phenanthroline units and COX-2 
inhibiting NSAID moieties within a single molecule, libraries of 
CSC-potent compounds can be prepared. The leading 
copper(II) complex, 3c was successfully encapsulated into PEG-
PLGA nanoparticles, 3c NP5, which were readily taken up by 
CSCs through an endocytic pathway. Strikingly, CSC uptake of 
3c NP5 was one order of magnitude greater than that of the 
unencapsulated copper(II) complex, 3c. Additionally, 3c NP5 
was 4-fold more cytotoxic towards CSCs than bulk cancer cells, 
which is moderately better than salinomycin (3-fold). The 
nanoparticle formulation, 3c NP5 is not only able to 
recapitulate the CSC-potency and -selectivity of the payload 
but also evoke a similar cellular response. The latter bodes 
well for future in vivo development, as one of the drawbacks 
of nanoparticle encapsulation as a strategy for drug delivery is 
the potential discrepancy in cellular mechanism of action of 
the nanoparticle formulation and its payload.54 Our results 
show, for the first time, that CSC-potent metal complexes can 
be encapsulated by polymeric nanoparticles and delivered into 
CSCs. Naturally the next step will be to study the nanoparticle 
formulation presented here, in in vivo systems. 
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